In this study, PSMA aptamer-smgl/siRNA chimera was made to stimulate protective antitumor immunity and it was suggested that the dose treatment of aptamer-siRNA chimeras can be further optimized to inhibit tumor (Pastor et al., 2010). The gene discussed is FOLH1; the disease is neoplasm.